KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Common Equity (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Common Equity for 17 consecutive years, with $7.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity rose 13.46% to $7.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $7.5 billion, a 13.46% increase, with the full-year FY2025 number at $7.5 billion, up 13.46% from a year prior.
  • Common Equity was $7.5 billion for Q4 2025 at Bio-Rad Laboratories, up from $6.7 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $15.3 billion in Q3 2021 to a low of $6.6 billion in Q4 2024.
  • A 5-year average of $9.1 billion and a median of $8.6 billion in 2022 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 73.74% in 2021, then crashed 44.71% in 2022.
  • Bio-Rad Laboratories' Common Equity stood at $13.7 billion in 2021, then fell by 29.74% to $9.6 billion in 2022, then fell by 9.09% to $8.7 billion in 2023, then decreased by 24.85% to $6.6 billion in 2024, then rose by 13.46% to $7.5 billion in 2025.
  • Per Business Quant, the three most recent readings for BIO's Common Equity are $7.5 billion (Q4 2025), $6.7 billion (Q3 2025), and $7.1 billion (Q2 2025).